Ensho Health today announced a non-interventional secondary use of data study whose objective is to develop a screening algorithm to improve early diagnosis of Fabry disease by Cardiologists (the "Study"). "Improving early detection of Fabry disease has long been a priority of our research and development team" said Dr. Taha Bandukwala, Ensho Health Co-Founder and Chief Medical Officer.
Fabry disease is a rare inherited disorder that is difficult to diagnose. The disease is progressive, and symptoms and risks of complications increase with age, necessitating earlier treatment. Many patients with undiagnosed Fabry disease interact with community cardiologists in the context of its cardiac comorbidities, enriching the rate of prevalence in this setting. Although Fabry disease can be definitively diagnosed through laboratory and genetic testing, identifying patients suitable for workup is a challenge and universal screening is impractical.
The Study will use electronic medical record data of specialty centres across Canada to improve an existing screening algorithm for early detection of Fabry disease known as ENS002. If effective, the resulting algorithm will be encoded in medical device software and deployed through Ensho data labs.
The Study is supported by Takeda Canada.
About Ensho Health
Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.